Payment overview · 2025
General Payments
$1,707.89
26 reported records · 14 companies
Healthcare provider profile · identity verified
Kate Meredith Smith, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · JACKSONVILLE, FL · NPI 1861431462
Verified facts
What the public records show
CMS Open Payments records show Kate Meredith Smith, APRN received $1,707.89 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $362.49 | 21.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $274.01 | 16.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $238.67 | 14.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $176.47 | 10.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $161.72 | 9.5% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $161.25 | 9.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $93.02 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.04 | 5.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.02 | 3.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.69 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.18 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.28 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.76 | 1.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.29 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,707.89 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $362.49 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $238.67 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $223.74 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $176.47 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $173.58 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $161.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $100.43 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $93.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $89.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 137 |
| Omeprazole | Omeprazole | 358 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 95 |
| Lisinopril | Lisinopril | 266 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 77 |
| Montelukast Sodium | Montelukast Sodium | 215 | 58 |
| Metformin Hcl | Metformin Hcl | 195 | 66 |
| Trazodone Hcl | Trazodone Hcl | 175 | 50 |
| Simvastatin | Simvastatin | 171 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 52 |
| Famotidine | Famotidine | 157 | 37 |
| Sertraline Hcl | Sertraline Hcl | 156 | 55 |
| Furosemide | Furosemide | 142 | 44 |
| Losartan Potassium | Losartan Potassium | 142 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 50 |
| Potassium Chloride | Potassium Chloride | 140 | 33 |
| Gabapentin | Gabapentin | 133 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 54 |
| Ozempic | Semaglutide | 116 | 27 |
| Meloxicam | Meloxicam | 109 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 24 |
| Bupropion Xl | Bupropion Hcl | 80 | 30 |
| Clonazepam | Clonazepam | 79 | 29 |
| Metformin Hcl Er | Metformin Hcl | 78 | 29 |
| Glipizide Er | Glipizide | 77 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 24 |
| Valsartan | Valsartan | 64 | 24 |
| Prednisone | Prednisone | 62 | 44 |
| Eliquis | Apixaban | 61 | 15 |
| Alprazolam | Alprazolam | 59 | 21 |
| Celecoxib | Celecoxib | 59 | 19 |
| Lansoprazole | Lansoprazole | 59 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 23 |
| Tramadol Hcl | Tramadol Hcl | 55 | 20 |
| Warfarin Sodium | Warfarin Sodium | 52 | 12 |
| Gemfibrozil | Gemfibrozil | 50 | 11 |
| Lamotrigine | Lamotrigine | 49 | suppressed |
| Jardiance | Empagliflozin | 48 | 18 |
| Cefuroxime | Cefuroxime Axetil | 47 | 35 |
| Allopurinol | Allopurinol | 45 | 15 |
| Ibuprofen | Ibuprofen | 45 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 11 |
| Pregabalin | Pregabalin | 44 | 12 |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 37 |
| Buspirone Hcl | Buspirone Hcl | 42 | 13 |
| Lorazepam | Lorazepam | 41 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 14 |
| Meclizine Hcl | Meclizine Hcl | 40 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Xarelto | Rivaroxaban | 36 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 12 |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 15 |
| Carvedilol | Carvedilol | 31 | 13 |
| Glipizide | Glipizide | 31 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 26 |
| Diazepam | Diazepam | 25 | 16 |
| Enulose | Lactulose | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Nystatin | Nystatin | 23 | 16 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Methsuximide | Methsuximide | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,707.89 · 26 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FLOWTRIEVER, GATTEX, KISUNLA, Leqembi, NURTEC ODT, REPATHA, REXULTI, SHINGRIX, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error